Showing results (11-20 of 43) with videos related to
Sort By:
Pageof 5
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 28, 2024
Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negativesIkjae Lee, Mark A Garret, Joanne Wuu, et al.Oncotarget|May 17, 2018
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancerAlvaro Avivar-Valderas, Robert McEwen, Amir Taheri-Ghahfarokhi, et al.Human Gene Therapy|January 22, 2016
Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic AcidemiaElizabeth A Harrington, Jennifer L Sloan, Irini Manoli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK InhibitorsRoz Brant, Alan Sharpe, Tom Liptrot, et al.Scientific Reports|September 8, 2019
Proliferation Tumour Marker Network (PTM-NET) for the identification of tumour region in Ki67 stained breast cancer whole slide imagesJesuchristopher Joseph, Martine P Roudier, Priya Lakshmi Narayanan, et al.Cancer Research|June 13, 2015
Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical SamplesMargaret H Veldman-Jones, Roz Brant, Claire Rooney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014Bristi Basu, Emma Dean, Martina Puglisi, et al.Nature Medicine|February 26, 2004
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivoElizabeth A Harrington, David Bebbington, Jeff Moore, et al.European Urology Oncology|November 5, 2025
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate CancerFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.Plos One|February 25, 2016
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous AmpliconClaire Rooney, Catherine Geh, Victoria Williams, et al.Pageof 5